Celesio AG / Key word(s): Miscellaneous 08.05.2012 21:26 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Non-cash impairment on discontinued operations During the course of compiling the financial statements for the quarter ending 31 March 2012, Celesio conducted the necessary impairment tests to calculate the value of discontinued operations as a result of the company's strategic realignment. In doing so, it determined that the revaluation of Pharmexx has now led to a non-cash impairment of 45 million EUR. The management board assumes that the company will generate 2012 EBITDA equal to or better than in the 2011 financial year, once adjusted for the non-recurring effect of the Operational Excellence Programme. We are expecting adjusted EBIT to follow a similar trend. Based on the preliminary figures for the first quarter of 2012, Celesio achieved revenues of around 5.64 billion EUR (2011: 5.50 billion EUR ), EBITDA adjusted for the non-recurring effect of the Operational Excellence Programme of nearly 140 million EUR (2011: 133 million EUR ) and EBIT adjusted for the same item of around 107 million EUR (2011: 103 million EUR ). Consequently, the company was able to increase revenues and earnings year-on-year based on comparable numbers. The completed financial statements for the quarter ending 31 March 2012 will be published on 14 May 2012, as planned. 08.05.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Germany Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-736 E-mail: investor@celesio.com Internet: www.celesio.com ISIN: DE000CLS1001 WKN: CLS100 Indices: MDAX Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime Standard), München, Stuttgart; Freiverkehr in Hamburg, Hannover; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Celesio AG: Non-cash impairment on discontinued operations
| Source: EQS Group AG